NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced today that the Center for Evidence-Based Psychiatry (CEBP) in Denmark has approved commencing enrollment of a clinical trial of ...

ANB032 was well tolerated across all doses with no safety signals observed; AD trial and all further investment in ANB032 will be discontinued; Anticipate top-line Phase 2b data i ...

IRVING, Texas, Dec. 11, 2024 (GLOBE NEWSWIRE) -- For the second year in a row, SCALE Healthcare has named U.S. Oral Surgery Management ( USOSM) President and CEO Richard Hall to its list of Most ...

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation ...

This meeting is not an official program of the ASH Annual Meeting.

Commercial Benefits In the commercial sector, overall enrollment decreased by 1% compared to 2022. Yet, DPPO plans—representing the dominant commercial dental product—saw a slight rise in market share ...

60 Degrees Pharmaceuticals has found that the total cumulative accessible market through the end of U.S. patent protection in December, 2035 for ARAKODA ® ( tafenoquine) for babesiosis may exceed ...

NANTES, France, December 11, 2024 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided a clinical update on Tedopi® (OSE-2101), the ‘off-the-shelf’ ...

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for ...

Nantes, France, le 11 décembre 2024, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) fait un point clinique sur les avancées de Tedopi® (OSE-2101), un vaccin thérapeutique ...